{"entity":{"id":"st-jude","kind":"institution","name":"St. Jude Children's Research Hospital","aka":["St. Jude"],"tldr":"The only NCI comprehensive cancer centre devoted to children, where Total Therapy protocols made childhood leukaemia curable; families are never billed for care.","summary":"Founded by Danny Thomas in 1962 and NCI comprehensive since 2008, St. Jude treats children with cancer and catastrophic diseases without charging families for treatment, travel, housing or food. Donald Pinkel's Total Therapy protocols pioneered combination chemotherapy with CNS-directed therapy in acute lymphoblastic leukaemia; by St. Jude's own figures ALL survival rose from about 4% when the hospital opened to about 94% today. The Pediatric Cancer Genome Project with Washington University (2010) sequenced hundreds of paediatric tumours, and St. Jude Cloud shares the data; the hospital opened the first proton centre dedicated to children in 2015 and runs molecularly risk-adapted trials in medulloblastoma, neuroblastoma and retinoblastoma. St. Jude Global works to raise childhood cancer survival in low- and middle-income countries, and Julie Park chairs its Department of Oncology.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/St._Jude_Children's_Research_Hospital","links":[{"label":"St. Jude Children's Research Hospital","url":"https://www.stjude.org"},{"label":"Clinical trials","url":"https://www.stjude.org/treatment/clinical-trials.html"},{"label":"St. Jude Cloud","url":"https://www.stjude.cloud"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["all-leukemia","medulloblastoma","neuroblastoma","retinoblastoma","osteosarcoma"],"sections":[],"technologies":["proton-therapy","wes-wgs","car-t","proton-therapy-systems"],"targets":[],"drugs":[],"companies":["childrens-oncology-group"],"institutions":["wustl-siteman"],"pathways":[],"terms":[],"trials":[],"people":["julie-park","james-r-downing","ching-hon-pui","amar-gajjar","robbie-majzner"],"bottlenecks":["b-global-access","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Memphis, TN","country":"US","lat":35.152,"lng":-90.043,"institutionType":"cancer-center","website":"https://www.stjude.org","nci":"comprehensive","programs":["Acute lymphoblastic leukaemia (Total Therapy)","Pediatric Cancer Genome Project","Proton therapy for children","St. Jude Global"]},"route":"/institutions/st-jude/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml-paediatric","kind":"cancer","name":"Acute myeloid leukaemia in children","route":"/cancers/aml-paediatric/"},{"id":"atrt","kind":"cancer","name":"Atypical teratoid/rhabdoid tumour (ATRT)","route":"/cancers/atrt/"},{"id":"craniopharyngioma","kind":"cancer","name":"Craniopharyngioma","route":"/cancers/craniopharyngioma/"},{"id":"ependymoma","kind":"cancer","name":"Ependymoma","route":"/cancers/ependymoma/"},{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/"},{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"},{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"},{"id":"all-ph-like","kind":"cancer","name":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","route":"/cancers/all-ph-like/"},{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/"},{"id":"medulloblastoma-shh","kind":"cancer","name":"SHH-activated medulloblastoma","route":"/cancers/medulloblastoma-shh/"},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/"},{"id":"medulloblastoma-wnt","kind":"cancer","name":"WNT-activated medulloblastoma","route":"/cancers/medulloblastoma-wnt/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/"},{"id":"proton-therapy-systems","kind":"technology","name":"Proton therapy machines: cyclotrons, synchrotrons and single-room systems","route":"/technologies/proton-therapy-systems/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"company":[{"id":"childrens-oncology-group","kind":"company","name":"Children's Oncology Group (COG)","route":"/companies/childrens-oncology-group/"},{"id":"hitachi","kind":"company","name":"Hitachi (particle therapy)","route":"/companies/hitachi/"}],"institution":[{"id":"aubmc-basile-cancer-institute","kind":"institution","name":"American University of Beirut Medical Center / Naef K. Basile Cancer Institute","route":"/institutions/aubmc-basile-cancer-institute/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"},{"id":"wustl-siteman","kind":"institution","name":"Siteman Cancer Center, Washington University","route":"/institutions/wustl-siteman/"}],"person":[{"id":"amar-gajjar","kind":"person","name":"Amar Gajjar","route":"/people/amar-gajjar/"},{"id":"ching-hon-pui","kind":"person","name":"Ching-Hon Pui","route":"/people/ching-hon-pui/"},{"id":"giles-robinson","kind":"person","name":"Giles W. Robinson","route":"/people/giles-robinson/"},{"id":"james-r-downing","kind":"person","name":"James R. Downing","route":"/people/james-r-downing/"},{"id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/"},{"id":"robbie-majzner","kind":"person","name":"Robbie G. Majzner","route":"/people/robbie-majzner/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"}],"idea":[{"id":"idea-cost-pooled-procurement-essential","kind":"idea","name":"Pool purchasing of essential cancer medicines across countries","route":"/ideas/idea-cost-pooled-procurement-essential/"}],"paper":[{"id":"paper-sherr-roberts-cdk-inhibitors-genesdev-1999","kind":"paper","name":"Sherr and Roberts 1999: CDK inhibitors as regulators of the G1 phase","route":"/key-papers/paper-sherr-roberts-cdk-inhibitors-genesdev-1999/"}],"collection":[{"id":"sjlife","kind":"collection","name":"St Jude Lifetime Cohort Study (SJLIFE)","route":"/collections/sjlife/"}],"trial":[{"id":"ccss","kind":"trial","name":"Childhood Cancer Survivor Study (CCSS)","route":"/trials/ccss/"},{"id":"sjmb12","kind":"trial","name":"SJMB12","route":"/trials/sjmb12/"}],"roadmap":[{"id":"paediatric-oncology-roadmap","kind":"roadmap","name":"Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first","route":"/roadmaps/paediatric-oncology-roadmap/"}]}}